Strickland; Corey

Patent Applications and Registrations

Patent applications and USPTO patent grants for Strickland; Corey.The latest application filed is for "anti-human pd-1 antibody crystals and methods of use thereof".

Company Profile

1.21.27

Strickland; Corey - Martinsville NJ
Strickland; Corey - North Plainfield NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-human Pd-1 Antibody Crystals And Methods Of Use Thereof App 20210317215 - Reichert; Paul ; et al.	2021-10-14
Crystals of anti-human PD-1 monoclonal antibodies Grant 11,014,986 - Reichert , et al. May 25, 2	2021-05-25
Crystals Of Anti-human Pd-1 Monoclonal Antibodies App 20180237524 - Reichert; Paul ; et al.	2018-08-23
C.difficile toxin B CROP domain peptides, antibodies and complexes thereof Grant 9,181,632 - Murgolo , et al. November 10, 2	2015-11-10
Cyclic amide BACE-1 inhibitors having a benzamide substituent Grant 9,062,007 - Cumming , et al. June 23, 2	2015-06-23
Heterocyclic Aspartyl Protease Inhibitors App 20150105354 - Zhu; Zhaoning ; et al.	2015-04-16
Heterocyclic aspartyl protease inhibitors Grant 8,778,980 - Zhu , et al. July 15, 2	2014-07-15
Cyclic Amide Bace-1 Inhibitors Having A Benzamide Substituent App 20140128361 - Cumming; Jared N. ; et al.	2014-05-08
Heterocyclic Aspartyl Protease Inhibitors App 20140057910 - Zhu; Zhaoning ; et al.	2014-02-27
Cyclic amine BACE-1 inhibitors having a benzamide substituent Grant 8,623,867 - Cumming , et al. January 7, 2	2014-01-07
Heterocyclic Aspartyl Protease Inhibitors App 20130018066 - Zhu; Zhaoning ; et al.	2013-01-17
Cyclic Amine Bace-1 Inhibitors Having A Benzamide Substituent App 20130004518 - Cumming; Jared N. ; et al.	2013-01-03
Cyclic amine BACE-1 inhibitors having a benzamide substituent Grant 8,278,334 - Cumming , et al. October 2, 2	2012-10-02
Heterocyclic aspartyl protease inhibitors Grant 8,242,112 - Zhu , et al. August 14, 2	2012-08-14
Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides Grant 8,034,907 - Taremi , et al. October 11, 2	2011-10-11
Heterocyclic Aspartyl Protease Inhibitors App 20110218194 - Zhu; Zhaoning ; et al.	2011-09-08
Heterocyclic aspartyl protease inhibitors Grant 7,973,067 - Zhu , et al. July 5, 2	2011-07-05
Cyclic amine bace-1 inhibitors having a heterocyclic substituent Grant 7,910,590 - Huang , et al. March 22, 2	2011-03-22
Modified Tumor Necrosis Factor-alpha Converting Enzyme And Methods Of Use Thereof App 20100184111 - Beyer; Brian M. ; et al.	2010-07-22
Cyclic Amine Bace-1 Inhibitors Having A Benzamide Substituent App 20100152138 - Cumming; Jared N. ; et al.	2010-06-17
Soluble, Stable Form Of Hdm2, Crystalline Forms Thereof And Methods Of Use Thereof App 20100136620 - Taremi; Shahriar Shane ; et al.	2010-06-03
Heterocyclic aspartyl protease inhibitors Grant 7,700,603 - Zhu , et al. April 20, 2	2010-04-20
Cyclic amine BACE-1 inhibitors having a benzamide substituent Grant 7,662,816 - Cumming , et al. February 16, 2	2010-02-16
Cyclic Amine Bace-1 Inhibitors Having A Heterocyclic Substituent App 20090312341 - Cumming; Jared N. ; et al.	2009-12-17
Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof Grant 7,632,920 - Taremi , et al. December 15, 2	2009-12-15
Heterocyclic Aspartyl Protease Inhibitors App 20090306047 - Zhu; Zhaoning ; et al.	2009-12-10
Heterocyclic Aspartyl Protease Inhibitors App 20090258868 - Zhu; Zhaoning ; et al.	2009-10-15
Cyclic amine BACE-1 inhibitors having a heterocyclic substituent Grant 7,598,250 - Cumming , et al. October 6, 2	2009-10-06
Heterocyclic aspartyl protease inhibitors Grant 7,592,348 - Zhu , et al. September 22, 2	2009-09-22
Modified Tumor Necrosis Factor-alpha Converting Enzyme And Methods Of Use Thereof App 20090221016 - Beyer; Brian M. ; et al.	2009-09-03
Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof App 20070148669 - Beyer; Brian M. ; et al.	2007-06-28
Heterocyclic aspartyl protease inhibitors App 20070072852 - Zhu; Zhaoning ; et al.	2007-03-29
Modified tumor necrosis factor-alpha converting enzyme and methods of use thereof Grant 7,138,264 - Beyer , et al. November 21, 2	2006-11-21
Heterocyclic aspartyl protease inhibitors App 20060111370 - Zhu; Zhaoning ; et al.	2006-05-25
Cyclic amine bace-1 inhibitors having a benzamide substituent App 20050119227 - Cumming, Jared N. ; et al.	2005-06-02
Cyclic amine BACE-1 inhibitors having a heterocyclic substituent App 20050043290 - Cumming, Jared N. ; et al.	2005-02-24
Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof App 20050037383 - Taremi, Shahriar Shane ; et al.	2005-02-17
Farnesyl protein transferase inhibitors Grant 6,800,636 - Guzi , et al. October 5, 2	2004-10-05
Beta-secretase crystals and methods for preparing and using the same App 20040014194 - Beyer, Brian M. ; et al.	2004-01-22
Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors App 20030134846 - Windsor, William T. ; et al.	2003-07-17
Farnesyl protein transferase inhibitors App 20030040520 - Guzi, Timothy ; et al.	2003-02-27
Farnesyl protein transferase inhibitors Grant 6,362,188 - Guzi , et al. March 26, 2	2002-03-26

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.